Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;136(5):458-465.e3.
doi: 10.1016/j.amjmed.2023.02.006. Epub 2023 Feb 21.

Long-Term Follow-Up After Acute Myocardial Infarction According to Beta-Blocker Dose

Susanne Bendesgaard Pedersen  1 , Jens Cosedis Nielsen  2 , Hans Erik Bøtker  2 , Aparna Udupi  3 , Jeffrey J Goldberger  4
Affiliations

Long-Term Follow-Up After Acute Myocardial Infarction According to Beta-Blocker Dose

Susanne Bendesgaard Pedersen et al. Am J Med. 2023 May.

Abstract

Objective: Our purpose was to examine the association between beta-blocker dose and mortality following acute myocardial infarction.

Methods: This nationwide cohort study enrolled all patients admitted for first-time acute myocardial infarction in Denmark between July 1, 2004 and December 31, 2014, using the Danish National Patient Registry. Patients alive 15 days after admission were followed until death, emigration, or December 31, 2014. Patients were categorized according to daily beta-blocker consumption (0%, >0%-12.5%, >12.5%-25%, >25%-50%, >50%-100%, or >100% of the currently recommended target dose) based on prescriptions registered in the Danish National Database of Reimbursed Prescriptions. Doses were continuously updated during follow-up. Mortality rate ratios (MRRs) were computed and adjusted for confounders using Cox proportional hazard regression.

Results: Among 65,125 patients followed, any beta-blocker dose was associated with significant mortality reduction compared with no treatment (adjusted MRR ≤ 0.92 [95% confidence interval {CI}: 0.86-0.98]). The largest reduction was observed within the first year for beta-blocker doses >25%-50% (adjusted MRR = 0.55 [95% CI: 0.50-0.60]). After 1 year, doses >50%-100% were associated with the largest mortality reduction (adjusted MRR = 0.58 [95% CI: 0.50-0.67]), but it did not differ significantly from that associated with doses >25%-50% (adjusted MRR = 0.68 [95% CI: 0.61-0.77]).

Conclusions: Any beta-blocker dose was associated with significant mortality reduction following acute myocardial infarction compared with no treatment. Doses >25%-50% of the currently recommended target dose were associated with maximal mortality reduction within the first year after acute myocardial infarction, suggesting that higher doses are unnecessary.

Keywords: Acute myocardial infarction; Beta-blocker; Cohort study; Dose; Mortality.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest

none.

Figures

Figure 1.
Figure 1.
Study inclusion and follow-up.
Figure 2.
Figure 2.
Adjusted mortality rate ratios according to daily beta-blocker dose during year 1 and years 1–10 after acute myocardial infarction. Whisker bars illustrate upper and lower 95% confidence intervals. *Adjusted for gender, age, type of myocardial infarction, beta-blocker use prior to myocardial infarction, cardiac interventions, comorbidity category, and co-medication. ref = reference.
See this image and copyright information in PMC

References

    1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes. JACC 2014;64(24):e139–228. - PubMed
    1. O’Gara PT, Kushner FG, Casey DE, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. JACC 2013;61(4)e78–140. - PubMed
    1. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomized trial. Lancet 1981;2:823–827. - PubMed
    1. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–1390. - PubMed
    1. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet 1999;353:9–13. - PubMed

Publication types

Substances